News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Cathy Qi

Articles by Cathy Qi

TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)

ByPedram Razavi,Judith Balmaña,Stephen Luen,Mario Campone,Laura Cortesi,Norikazu Masuda,Kyong Hwa Park,Qingyuan Zhang,Emily Nizialek,Cathy Qi,Karen Cui,Sibylle Loibl,Mark Robson, MD,Filipa Lynce

April 22nd 2025

Latest Updated Articles

TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)
Published: April 22nd 2025 | Updated:

Trending on CancerNetwork

Investigators Launch Phase 3 Trial of Calderasib Combo in Advanced NSCLC

Zanidatamab Regimens Extend PFS/OS in Advanced/Metastatic Gastric Cancer

Sevabertinib Earns Breakthrough Therapy Designation for HER2+ NSCLC in US/China

Developers Submit NDA to FDA for Rusfertide in Polycythemia Vera

Supervised Resistance Exercise May Help QOL Outcomes in Colorectal Cancer